Alzheimer’s Drug Discovery Foundation   Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: New York NY United States (1998)

Organization Overview

First Clinical Trial
2017
NCT03298672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alzheimer's Drug Discovery Foundation | Alzheimer’s Drug Discovery Foundation

Active Ingredients

Drugs in Phase 3 Trials (1)

nabilone (cesamet) (1 trial)

Drugs in Phase 2 Trials (5)

ory-2001 (1 trial)

pepinemab (1 trial)

rotigotine (neupro) (1 trial)

sodium phenylbutyrate (buphenyl) (1 trial)

tauroursodeoxycholic acid (1 trial)

Drugs in Phase 1 Trials (2)

ath-1017 (1 trial)

dabigatran (pradaxa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Cognitive Dysfunction (Phase 1)

Psychomotor Agitation (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8